Search the Newsreel

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, a 66% year-over-year increase, driven by strong Amtagvi demand and achieving a 56% gross margin. The company is expanding its TIL therapy platform into broader solid tumor indications like non-small cell lung cancer and …

IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast

Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns

Iovance Biotherapeutics (IOVA) stock has seen a significant 221.8% return over the past year, but its current valuation suggests it is now fairly priced rather than cheap. The company scores a mixed 4 out of 6 on Simply Wall St's valuation checks, with a …

Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance

Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?

Iovance Biotherapeutics (IOVA) is gaining investor attention after reporting improved Q2 2026 results, including higher revenue and a narrower net loss, while reaffirming full-year revenue guidance of US$350-370 million. Despite a recent share price surge and a narrative suggesting it's undervalued at $18 compared …

Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 100% in the second quarter, now holding 818,913 shares valued at $3.4 million. This move comes as Iovance Biotherapeutics reported strong quarterly revenue growth of 65.7% year-over-year, beating analyst …

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics (NASDAQ: IOVA) recently reported strong Q2 earnings, with revenue increasing by 66% due to high demand for its cancer treatment, Amtagvi. The company also significantly reduced its net losses, leading to a surge in stock value and a new 52-week high. Despite …

What is HC Wainwright's Forecast for IOVA Q3 Earnings?

Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Iovance Biotherapeutics, Inc. recently reported its latest quarterly results, surpassing analyst revenue and earnings estimates. This positive performance has led analysts to revise their forecasts upwards, suggesting increased optimism about the company's future earnings potential. The market reacted positively, with the stock price climbing …

Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com

This article reports on the filing of a Form 8K by Iovance Biotherapeutics Inc. The filing date is stated as August 6th. The article, published by Investing.com, provides no further details beyond the announcement of the 8K filing.

Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains

Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside

Iovance Biotherapeutics, Inc. (IOVA) has seen its average 12-month stock price target raised to $8.67 from $8.22 by 9 analysts, implying a potential upside of approximately 100% from its Aug. 5 closing price. The consensus rating for the stock remains "Buy," with 7 analysts …

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

Iovance Biotherapeutics (IOVA) closed at $6.21, with Wall Street analysts setting a mean price target of $7.95, suggesting a 28% upside. While an impressive consensus price target is noted, the article cautions against relying solely on these targets due to potential analyst optimism and …

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

IOVANCE BIOTHERAPEUTICS, INC. 2Q 2026: Revenue $99.3M, EPS $(0.11) — 10-Q Summary

IOVANCE BIOTHERAPEUTICS, INC. reported its second-quarter 2026 results, showing significant improvement with revenue of $99.3M and a narrowed net loss of $47.3M. The company's diluted EPS improved to $(0.11), driven by commercial growth, including increased Amtagvi® infusions and higher Proleukin® sales. IOVANCE has also …

Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) rocketed to a fresh 52-week high on Thursday, clocking as much as 47 percent gains, after management reported a 66 percent jump in revenues that signaled the strengthening demand for its treatment for advanced melanoma. In intra-day trading, the stock …

Iovance plans full-year 2026 revenue guidance update in Q3 while maintaining $1B+ U.S. peak sales assumptions

Earnings Call Insights: Iovance Biotherapeutics (IOVA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was our strongest yet." (Interim CEO, President, General Counsel, Corporate Secretary & Director Frederick Vogt) "We reported $99.3 million in revenue driven by record Amtagvi demand." "Second quarter …

Why Investors Are Watching These Healthcare Movers

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. ClearOne Advances Toward Neurotechnology Transformation ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into …

Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30%

Iovance Biotherapeutics (NASDAQ: IOVA) reported stronger-than-expected Q2 2026 results, with adjusted loss per share narrower than anticipated and revenue exceeding forecasts, driven by robust sales of its cancer therapy Amtagvi. Shares jumped over 30% in premarket trading. The company also announced improved gross margins, …

Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations

Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand

Iovance stock surges as Amtagvi powers Q2 beat (IOVA:NASDAQ)

Iovance Biotherapeutics (IOVA) stock surged over 40% to a new 52-week high after reporting Q2 2026 earnings that significantly exceeded Wall Street expectations. The strong performance was attributed to its cancer therapy, Amtagvi. The company maintained its revenue outlook under review.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

IOVA Stock Grants Signal Aggressive Post-Amtagvi Expansion

Iovance Biotherapeutics Inc. (IOVA) has granted inducement stock options for 139,930 shares to 17 new non-executive hires, signaling an aggressive post-Amtagvi expansion. These grants, with a $4.66 strike price and a three-year vesting period, suggest management's confidence in long-term growth following the FDA approval …

Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com

Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $5.97, reflecting a 64.39% appreciation over the past year. The company, which specializes in cancer immunotherapies, currently trades at $6.21 with a market capitalization of $1.94 billion. This milestone follows better-than-expected Q2 2026 results, …

Iovance Biotherapeutics Stock Grants Signal Post-Amtagvi Expansion

Iovance Biotherapeutics (NASDAQ: IOVA) is experiencing a 31.57% stock increase driven by positive sentiment surrounding its Amtagvi trial progress and a new hiring wave. The company granted inducement stock options for 139,930 shares to 17 new non-executive hires, indicating a significant expansion post-FDA approval …

IOVANCE BIOTHERAPEUTICS ($IOVA) Releases Q2 2026 Earnings

Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q2 Revenue $99.3M, vs. FactSet Est of $87.8M

Iovance Biotherapeutics, Inc. (IOVA) announced strong Q2 revenue, reaching $99.3 million, significantly surpassing FactSet's estimated $87.8 million. This positive financial performance was released alongside other company updates, including recent regulatory approvals for its Amtagvi therapy in Australia and FDA clearance for a new clinical …

Iovance Biotherapeutics reports record Q2 revenue ~$99.3M, gross margin 56%

Iovance Biotherapeutics reported record second-quarter 2026 product revenue of $99.3 million with a 56% gross margin, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance following these robust results and expects continued gross margin improvement. Key highlights include …

Iovance Biotherapeutics Reports Record Second Quarter 2026

Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, a 66% increase year-over-year, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million and expects to provide an update in the third …